Wipro Partners with Transcell Oncologics to Transform Vaccine Safety Assessment
May 05 2021 - 9:39AM
Business Wire
Use of the Wipro HOLMES® Augmented Intelligence
platform will lead to safer vaccines and faster rollout to
patients
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading
global information technology, consulting and business process
services company, today announced a partnership with Transcell
Oncologics to transform vaccine safety assessment using augmented
intelligence (AI). This partnership combines Transcell’s innovative
stem cell technology with the advanced augmented intelligence
capabilities of Wipro HOLMES® to improve the safety of global
vaccine immunization programs.
By applying AI to the vaccine development process, our solution
is capable of predicting adverse neurovirulent impacts resulting
from vaccinations. Currently, vaccine safety assessment often
includes testing on animals to measure adverse impacts. Using Wipro
HOLMES® instead, researchers and biopharmaceutical companies have a
new and fully viable solution and alternative. Wipro HOLMES® can
also be integrated into any existing workflow, including quality
control tests in vaccine production, batchwise release and other
safety evaluation assays.
This partnership will also expand the Wipro HOLMES® solutions
available to life science companies. The solution applies AI for
drug repurposing and Messenger Ribonucleic Acid (mRNA) based
platform for biodefense. It enables the testing of new vaccines by
applying augmented intelligence to stem cell research and measuring
safety and potency. This is the first in a series of next
generation solutions that the partnership will offer to determine
the safety and efficacy of a wide-range of products from vaccines
to prescription medications, cosmetics and more.
Harmeet Chauhan, Global Head - Engineering and R&D, Wipro
Limited said, “Enhancing neurovirulence safety assessment
through augmented intelligence is a huge step forward in vaccine
research and development. This innovative technology allows life
science companies and vaccine manufacturers to develop, trial and
release safer and more effective vaccines for people around the
world. Our partnership with Transcell Oncologics will bring the
best of AI and stem cell technology to researchers, medical
professionals and ultimately patients through safe, accelerated
vaccination programs.”
Dr. Subhadra Dravida, Founder CEO, Transcell said, “This
exciting partnership combines the biotechnology capabilities of
Transcell Oncologics’s Transtoxbio vertical with the advanced
augmented intelligence capabilities of Wipro HOLMES® . Deriving new
and advanced insights from the use of stem cells in an in vitro
setting transforms vaccine safety assessment. This breakthrough
process will lead to new medical treatments and accelerate
innovation and vaccine availability that is vital to saving
lives.”
In February 2021, the Transcell-Wipro HOLMES® solution for
neurovirulence was presented with the Best IP Managed Stemcell
award at the ChemTECH BioPharma World.IE Conference.
About Wipro Limited
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading
global information technology, consulting and business process
services company. We harness the power of cognitive computing,
hyper-automation, robotics, cloud, analytics and emerging
technologies to help our clients adapt to the digital world and
make them successful. A company recognized globally for its
comprehensive portfolio of services, strong commitment to
sustainability and good corporate citizenship, we have over 190,000
dedicated employees serving clients across six continents.
Together, we discover ideas and connect the dots to build a better
and a bold new future.
Forward-looking and Cautionary Statements
The forward-looking statements contained herein represent
Wipro’s beliefs regarding future events, many of which are by their
nature, inherently uncertain and outside Wipro’s control. Such
statements include, but are not limited to, statements regarding
Wipro’s growth prospects, its future financial operating results,
and its plans, expectations and intentions. Wipro cautions readers
that the forward-looking statements contained herein are subject to
risks and uncertainties that could cause actual results to differ
materially from the results anticipated by such statements. Such
risks and uncertainties include, but are not limited to, risks and
uncertainties regarding fluctuations in our earnings, revenue and
profits, our ability to generate and manage growth, complete
proposed corporate actions, intense competition in IT services, our
ability to maintain our cost advantage, wage increases in India,
our ability to attract and retain highly skilled professionals,
time and cost overruns on fixed-price, fixed-time frame contracts,
client concentration, restrictions on immigration, our ability to
manage our international operations, reduced demand for technology
in our key focus areas, disruptions in telecommunication networks,
our ability to successfully complete and integrate potential
acquisitions, liability for damages on our service contracts, the
success of the companies in which we make strategic investments,
withdrawal of fiscal governmental incentives, political
instability, war, legal restrictions on raising capital or
acquiring companies outside India, unauthorized use of our
intellectual property and general economic conditions affecting our
business and industry. The conditions caused by the COVID-19
pandemic could decrease technology spending, adversely affect
demand for our products, affect the rate of customer spending and
could adversely affect our customers’ ability or willingness to
purchase our offerings, delay prospective customers’ purchasing
decisions, adversely impact our ability to provide on-site
consulting services and our inability to deliver our customers or
delay the provisioning of our offerings, all of which could
adversely affect our future sales, operating results and overall
financial performance. Our operations may also be negatively
affected by a range of external factors related to the COVID-19
pandemic that are not within our control.
Additional risks that could affect our future operating results
are more fully described in our filings with the United States
Securities and Exchange Commission, including, but not limited to,
Annual Reports on Form 20-F. These filings are available at
www.sec.gov. We may, from time to time, make additional written and
oral forward-looking statements, including statements contained in
the company’s filings with the Securities and Exchange Commission
and our reports to shareholders. We do not undertake to update any
forward-looking statement that may be made from time to time by us
or on our behalf.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210505005678/en/
Media Contact: Shraboni Banerjee Wipro Limited
shraboni.banerjee@wipro.com
Wipro (NYSE:WIT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Wipro (NYSE:WIT)
Historical Stock Chart
From Sep 2023 to Sep 2024